Cell and gene therapies have been grabbing news headlines, both for their potential to cure rare diseases and for their million-dollar price tags. Milliman pharmacists and healthcare experts explain why state Medicaid agencies are particularly affected and the strategies many are using for predicting uptake and covering these high costs. 

You can read the episode transcript on our website

Podden och tillhörande omslagsbild på den här sidan tillhör Milliman, Inc.. Innehållet i podden är skapat av Milliman, Inc. och inte av, eller tillsammans med, Poddtoppen.

Senast besökta

Critical Point

How can Medicaid pay for cell and gene therapies?

00:00